Keytruda Approved for Advanced Melanoma

September 7, 2014 1:07 PM

3 0

Melanoma, accounting for about 5% of new cancers in the United States, is expected to be diagnosed in more than 76,000 Americans and about 9,710 are projected to die from it this year, the FDA said in a news release.

Keytruda is the first approved drug that blocks the cellular pathway PD-1 and is intended for use following treatment with ipilimumab. For melanoma patients whose tumors express the gene mutation BRAF V600, Keytruda is intended for use after treatment with ipilimumab and a BRAF inhibitor.

Also read: FDA staff flags concerns about Allergan, Serenity Pharma urinary drug

Read more

To category page